For patients

• A disease of all the tissues of the diarthrodial synovial joint (note: freely moveable joints, such as the knee and shoulder)
• Disorder of diverse aetiologies (note: origins)
• Can affect the small and large joints; either individually (localized) or in combination (generalized)

• Can be attributed to wear and tear of the joints (i.e. degenerative joint disease)

• Genetic influence
• Body mass index (BMI) correlates with the presence of osteoarthritis (OA)
  • Link between obesity and osteoarthritis of the knee is more consistent in women with the biggest prevalence in knee osteoarthritis
  • A study in middle-aged women it was suggested that the risk of knee osteoarthritis increases by 35% for every 5kg of body weight gain
• Gender
• Below age 45 osteoarthritis (OA) is more common in men and it frequently involves two joints
• Increasing age – at least up to the age of 70
• Injury to the joint (post-traumatic)
• Joint hyper-mobility or instability
• Prolonged occupational or sports stress
• Abnormalities of the biomaterials of the joint, usually the articular cartilage
• Abnormalities of the biomechanics of the joint, usually due to the abnormal joint structure, resulting in abnormalities in the distribution of loading forces across the joint

• Pain
• Stiffness

At the diseased joint when moving or after a period of rest (first mobility)

• The greatest incidence of OA occurs at 45 years, when OA develops in the interphalangeal joints and the carpometacarpal (CMC) joint. This is then followed by the knee joint and the hip.
• The prevalence of OA of the knee among adults aged 55 to 74 years is greater in women than in men

Hyaluronic Acid (HA) falls under the category of viscosupplementation.
Hyaluronic acid is found in the synovial joint. In OA patients, the level of HA is greatly diminished in molecular weight and concentration.

Viscosupplementation is the term used to indicate the administration of hyaluronic acid (HA) into the synovial fluid to help regain the natural balance which has been lost in an OA joint.

RenehaVis™ is a product containing 2 different HAs in different concentrations for knee and hip osteoarthitis treatment. It is a synovial viscosupplement intended to be used for the relief of symptoms of osteoarthritis of the knee and hip by providing support and lubrication to the joint. RenehaVis™ is an innovative product which has shown in clinical trials to help patients experience less pain more quickly and more effectively than other Hyaluronic Acid products in the knee.

RenehaVis™ an be used for grade 1 to 3 medial compartment osteoarthritis. RenehaVis™ is for injection into the synovial space of a joint of patients affected by the early stages of osteoarthritis once a week for up to three injections depending on the severity of the degenerative change to the joint.

In the published clinical study, RenehaVis™ efficacy was seen by the second injection compared to other study treatments where walking pain was significantly improved. RenehaVis™ patients reported more global satisfaction compared to the patients using other products.

Patients are usually asked to wait a couple of hours before resuming regular activities, with a slow progression especially if effort is needed.

Although, it is proven that patients that use viscosupplementation may delay the progression of the disease, there has been no clinical evidence of the reformation of the cartilage layer found in the knee of OA patients.

We have a network of distributors worldwide. Please contact the distributor in your market or you may also contact us.